A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-525102-38-00

Enrollment

125

Registered

2026-08-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elevated lipoprotein(a)

Brief summary

Percent Change from Baseline in Lipoprotein (a) (Lp(a)) at Week 8, Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8, Number of Participants who Experience One or More Adverse Events (AEs), Number of Participants who Discontinue Study Intervention Due to an AE

Detailed description

Percent Change from Baseline in LDL-C at Week 8 (enlicitide monotherapy vs. placebo), Percent Change from Baseline in LDL-C at Week 8 (MK-7262 monotherapy vs. placebo), Percent Change from Baseline in Lp(a) at Week 8 (MK-7262 + enlicitide vs. MK-7262 monotherapy), Percent Change from Baseline in LDL-C at Week 8 (MK-7262 + enlicitide vs. enlicitide monotherapy), Percentage of Participants with Lp(a) <125 nmol/L at Week 8, Percentage of Participants with Lp(a) <75 nmol/L at Week 8, Percent Change from Baseline in Lp(a) at Week 12, Percent Change from Baseline in LDL-C at Week 12

Interventions

DRUGMK-0616

DRUGPlacebo to MK-7262

DRUGMK-7262

DRUGPlacebo to MK-0616

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percent Change from Baseline in Lipoprotein (a) (Lp(a)) at Week 8, Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8, Number of Participants who Experience One or More Adverse Events (AEs), Number of Participants who Discontinue Study Intervention Due to an AE	—

Secondary

Measure	Time frame
Percent Change from Baseline in LDL-C at Week 8 (enlicitide monotherapy vs. placebo), Percent Change from Baseline in LDL-C at Week 8 (MK-7262 monotherapy vs. placebo), Percent Change from Baseline in Lp(a) at Week 8 (MK-7262 + enlicitide vs. MK-7262 monotherapy), Percent Change from Baseline in LDL-C at Week 8 (MK-7262 + enlicitide vs. enlicitide monotherapy), Percentage of Participants with Lp(a) <125 nmol/L at Week 8, Percentage of Participants with Lp(a) <75 nmol/L at Week 8, Percent Change from Baseline in Lp(a) at Week 12, Percent Change from Baseline in LDL-C at Week 12	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 19, 2026